2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
The primary objective is to determine the time until maximum effect is reached of inhaled levodopa on motor function of Parkinson's disease patients during an off period. The secondary objectives are to determine the clinical improvement of…